ResMed, a developer of medical equipment for respiratory disorders, has enrolled 1,325 patients in SERVE-HF, an international, randomized study designed to determine sleep-disordered breathing in heart failure patients.
The study will examine the impact of treatment of central sleep apnea on morbidity and mortality in a heart failure population. It will provide proof of the health impact of effectively treating heart failure patients who have central sleep-disordered breathing.
The study, which began in 2008, is expected to complete by mid-2015, while results are expected to be disclosed in the first half of 2016.
The SERVE-HF study is currently being conducted across more than 80 locations in Germany, France, the UK, Norway, Sweden, Denmark, Finland, Australia, Switzerland, the Netherlands and the Czech Republic.
The main objective of the study is to find whether managing CSA-CSR with the company's PaceWave proprietary Minute Ventilation ASV technology increases survival rates and decreases the burden of hospitalizations in the patient population.
Commenting on enrollment, SERVE-HF co-principal investigator Martin Cowie said, "The aim of SERVE-HF is to not only assess survival rates, but also to see if Adaptive Servo-Ventilation improves quality of life, sleep and physiologic changes associated with heart failure."
